Weishi's new drug, ® (FYCOMPA®), has been approved by China's State Drug Administration
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
recently, the StateMedicines(http://Administration of China has approved the use of the WeishiNew Drug(http://The ® (FYCOMPA®) for the use of adults and children 12 years and older with partial seizures (accompanied or not accompanied by secondary full-blown seizures)The ® is an innovative anti-epilepticdrug developed by the Tsukuba Research Institute,the http:// orally once a dayThe ® is a highly selective, non-competitive AMPA receptor antagonist that reduces overexcitement in neurons associated with seizures by targeting the inhibition of glutamate activity in the synaptic after-membrane AMPA receptor.The ® has been approved in more than 60 countries worldwide for the use of partial seizures (accompanied or not with secondary full-blown seizures) in children 12 years of age and aboveThe ® has been approved in 55 countries around the world for the use of primary and comprehensive severe seizures in patients with epilepsy 12 years of age and abovein the United States, the ® has been approved for use in children 4 years of age and above for partial seizures (accompanied by or non-secondary full-blown seizures) single-drug and additional treatment.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
